Accustem Sciences, Inc: AccuStem's StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
LONDON and PHOENIX, March 01, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC PINK: ACMSY), a life sciences company dedicated to improving outcomes for patients with cancer, today announced publication
Source: finanznachrichten.de